ALX ONCOLOGY HOLDINGS INC Research and Development Expense
ALX ONCOLOGY HOLDINGS INC (ALXO) reported Research and Development Expense of $13.14 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-06
- ALX ONCOLOGY HOLDINGS INC research and development expense for the quarter ending 2026-06-30 was $13.14M, a 27.10% decline year-over-year.
- ALX ONCOLOGY HOLDINGS INC research and development expense for the quarter ending 2026-03-31 was $13.61M, a 43.04% decline year-over-year.
- ALX ONCOLOGY HOLDINGS INC research and development expense for the quarter ending 2025-12-31 was $17.64M, a 25.02% decline year-over-year.
- ALX ONCOLOGY HOLDINGS INC research and development expense for the quarter ending 2025-09-30 was $17.44M, a 34.11% decline year-over-year.
- ALX ONCOLOGY HOLDINGS INC research and development expense for fiscal 2025 was $77.00M, a 33.84% decline from fiscal 2024.
- ALX ONCOLOGY HOLDINGS INC research and development expense for fiscal 2024 was $116.37M, a 17.93% decline from fiscal 2023.
- ALX ONCOLOGY HOLDINGS INC research and development expense for fiscal 2023 was $141.79M, a 44.10% increase from fiscal 2022.
- ALX ONCOLOGY HOLDINGS INC research and development expense for fiscal 2022 was $98.40M, a 63.54% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $13.14M 10-Q · filed 2026-08-06 | $26.74M 10-Q · filed 2026-08-06 | $44.39M derived: sum of 3 quarters · filed 2026-08-06 | $61.83M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $13.61M 10-Q · filed 2026-05-08 | $31.25M derived: sum of 2 quarters · filed 2026-05-08 | $48.69M derived: sum of 3 quarters · filed 2026-05-08 | $66.71M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $17.64M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $35.09M derived: sum of 2 quarters · filed 2026-03-09 | $53.11M derived: sum of 3 quarters · filed 2026-08-06 | $77.00M 10-K · filed 2026-03-09 |
| 2025-09-30 | $17.44M 10-Q · filed 2025-11-07 | $35.46M derived: sum of 2 quarters · filed 2026-08-06 | $59.35M 10-Q · filed 2025-11-07 | $82.88M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $18.02M 10-Q · filed 2026-08-06 | $41.91M 10-Q · filed 2026-08-06 | $65.44M derived: sum of 3 quarters · filed 2026-08-06 | $91.91M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $23.89M 10-Q · filed 2026-05-08 | $47.42M derived: sum of 2 quarters · filed 2026-05-08 | $73.89M derived: sum of 3 quarters · filed 2026-05-08 | $108.54M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $23.53M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $50.00M derived: sum of 2 quarters · filed 2026-03-09 | $84.66M derived: sum of 3 quarters · filed 2026-03-09 | $116.37M 10-K · filed 2026-03-09 |
| 2024-09-30 | $26.47M 10-Q · filed 2025-11-07 | $61.12M derived: sum of 2 quarters · filed 2025-11-07 | $92.84M 10-Q · filed 2025-11-07 | $134.63M derived: sum of 4 quarters · filed 2026-03-09 |
| 2024-06-30 | $34.65M 10-Q · filed 2025-08-12 | $66.37M 10-Q · filed 2025-08-12 | $108.15M derived: sum of 3 quarters · filed 2026-03-09 | $153.92M derived: sum of 4 quarters · filed 2026-03-09 |
| 2024-03-31 | $31.72M 10-Q · filed 2025-05-08 | $73.50M derived: sum of 2 quarters · filed 2026-03-09 | $119.27M derived: sum of 3 quarters · filed 2026-03-09 | $148.75M derived: sum of 4 quarters · filed 2026-03-09 |
| 2023-12-31 | $41.78M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $87.55M derived: sum of 2 quarters · filed 2026-03-09 | $117.03M derived: sum of 3 quarters · filed 2026-03-09 | $141.79M 10-K · filed 2026-03-09 |
| 2023-09-30 | $45.77M 10-Q · filed 2024-11-07 | $75.25M derived: sum of 2 quarters · filed 2024-11-07 | $100.01M 10-Q · filed 2024-11-07 | $125.21M derived: sum of 4 quarters · filed 2025-03-06 |
| 2023-06-30 | $29.48M 10-Q · filed 2024-08-12 | $54.24M 10-Q · filed 2024-08-12 | $79.44M derived: sum of 3 quarters · filed 2025-03-06 | $108.82M derived: sum of 4 quarters · filed 2025-03-06 |
| 2023-03-31 | $24.76M 10-Q · filed 2024-05-09 | $49.96M derived: sum of 2 quarters · filed 2025-03-06 | $79.34M derived: sum of 3 quarters · filed 2025-03-06 | $106.09M derived: sum of 4 quarters · filed 2025-03-06 |
| 2022-12-31 | $25.20M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $54.58M derived: sum of 2 quarters · filed 2025-03-06 | $81.33M derived: sum of 3 quarters · filed 2025-03-06 | $98.40M 10-K · filed 2025-03-06 |
| 2022-09-30 | $29.38M 10-Q · filed 2023-11-13 | $56.13M derived: sum of 2 quarters · filed 2023-11-13 | $73.20M 10-Q · filed 2023-11-13 | $94.10M derived: sum of 4 quarters · filed 2024-03-07 |
| 2022-06-30 | $26.75M 10-Q · filed 2023-08-10 | $43.82M 10-Q · filed 2023-08-10 | $64.72M derived: sum of 3 quarters · filed 2024-03-07 | $82.93M derived: sum of 4 quarters · filed 2024-03-07 |
| 2022-03-31 | $17.07M 10-Q · filed 2023-05-11 | $37.97M derived: sum of 2 quarters · filed 2024-03-07 | $56.18M derived: sum of 3 quarters · filed 2024-03-07 | $67.39M derived: sum of 4 quarters · filed 2024-03-07 |
| 2021-12-31 | $20.89M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-07 | $39.11M derived: sum of 2 quarters · filed 2024-03-07 | $50.32M derived: sum of 3 quarters · filed 2024-03-07 | $60.17M 10-K · filed 2024-03-07 |
| 2021-09-30 | $18.21M 10-Q · filed 2022-11-08 | $29.43M derived: sum of 2 quarters · filed 2022-11-08 | $39.28M 10-Q · filed 2022-11-08 | $51.42M derived: sum of 4 quarters · filed 2023-03-09 |
| 2021-06-30 | $11.21M 10-Q · filed 2022-08-08 | $21.06M 10-Q · filed 2022-08-08 | $33.20M derived: sum of 3 quarters · filed 2023-03-09 | $38.53M derived: sum of 4 quarters · filed 2023-03-09 |
| 2021-03-31 | $9.85M 10-Q · filed 2022-05-09 | $21.99M derived: sum of 2 quarters · filed 2023-03-09 | $27.32M derived: sum of 3 quarters · filed 2023-03-09 | $34.98M derived: sum of 4 quarters · filed 2023-03-09 |
| 2020-12-31 | $12.14M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $17.47M derived: sum of 2 quarters · filed 2023-03-09 | $25.13M derived: sum of 3 quarters · filed 2023-03-09 | $28.96M 10-K · filed 2023-03-09 |
| 2020-09-30 | $5.33M 10-Q · filed 2021-11-12 | $12.99M derived: sum of 2 quarters · filed 2021-11-12 | $16.82M 10-Q · filed 2021-11-12 | $23.55M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | $7.66M 10-Q · filed 2021-08-12 | $11.49M 10-Q · filed 2021-08-12 | $18.23M derived: sum of 3 quarters · filed 2022-02-28 | $20.44M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | $3.83M 10-Q · filed 2021-05-17 | $10.56M derived: sum of 2 quarters · filed 2022-02-28 | $12.77M derived: sum of 3 quarters · filed 2022-02-28 | $16.40M derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | $6.74M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $8.95M derived: sum of 2 quarters · filed 2022-02-28 | $12.57M derived: sum of 3 quarters · filed 2022-02-28 | $16.31M 10-K · filed 2022-02-28 |
| 2019-09-30 | $2.21M 10-Q · filed 2020-11-12 | $5.84M derived: sum of 2 quarters · filed 2020-11-12 | $9.57M 10-Q · filed 2020-11-12 | |
| 2019-06-30 | $3.63M 10-Q · filed 2020-08-27 | $7.36M 10-Q · filed 2020-08-27 | ||
| 2018-12-31 | $11.27M 10-K · filed 2021-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |